A protocol for a multicentre randomised controlled trial of continuous beta-lactam infusion compared with intermittent beta-lactam dosing in critically ill patients with severe sepsis: The BLING II study

Critical Care and Resuscitation

Volumn 15, Issue 3, 2013, Pages 179-185

  Dulhunty, Joel M ^a   Roberts, Jason A ^a,b,k   Davis, Joshua S ^c,d   Webb, Steven A R ^e   Bellomo, Rinaldo ^f   Gomersall, Charles ^g,j   Shirwadkar, Charudatt ^h   Eastwood, Glenn M ^f,l   Myburgh, John ⁱ   Paterson, David L ^a   Starr, Therese ^a   Udy, Andrew A ^a   Paul, Sanjoy K ^a   Lipman, Jeffrey ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d JOHN HUNTER HOSPITAL   (Australia)

^e UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^f AUSTIN HOSPITAL   (Australia)

^g PRINCE OF WALES HOSPITAL   (Australia)

^h BLACKTOWN HOSPITAL   (Australia)

ⁱ GEORGE INSTITUTE FOR GLOBAL HEALTH   (Australia)

^j CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^k National Health and Medical Research Council Career Development   (Australia)

^l Intensive Care Unit Research   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM;

ADULT; AGED; ARTICLE; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTENSIVE CARE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEPSIS; TREATMENT OUTCOME;

ADULT; AGED; BETA-LACTAMS; CRITICAL CARE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEPSIS; TREATMENT OUTCOME;

EID: 84887566270     PISSN: 14412772     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Dulhunty JM, Paterson D, Webb SA, Lipman J. Antimicrobial utilisation in 37 Australian and New Zealand intensive care units. Anaesth Intensive Care 2011; 39: 231-237.
2. Corona A, Bertolini G, Lipman J, et al. Antibiotic use and impact on outcome from bacteraemic critical illness: the BActeraemia Study in Intensive Care (BASIC). J Antimicrob Chemother 2010; 65: 1276-1285.
3. Mouton JW, Vinks AA. Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598-606.
4. Roberts JA, Paratz J, Paratz E, et al. Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents 2007; 30: 11-18.
5. Abdul-Aziz MH, Dulhunty JM, Bellomo R, et al. Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care 2012; 2: 37.
6. Dulhunty JM, Webb SA, Paterson DL, et al. A survey of antibiotic prescribing practices in Australian and New Zealand intensive care units. Crit Care Resusc 2010; 12: 162-170.
7. Roberts JA, Kirkpatrick CM, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimi-crob Chemother 2009; 64: 142-150.
8. Kasiakou SK, Sermaides GJ, Michalopoulos A, et al. Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581-589.
9. Roberts JA, Webb S, Paterson D, et al. A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med 2009; 37: 2071-2078.
10. Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis 2013; 56: 236-244.
11. Roberts JA, Boots R, Rickard CM, et al. Is continuous infusion ceftriaxone better than once-a-day dosing in intensive care? A randomized controlled pilot study. J Antimicrob Chemother 2007; 59: 285-291.
12. Levy MM, Fink M P, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-538.
13. Vincent JL, Angus DC, Artigas A, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial. Crit Care Med 2003; 31: 834-840.
14. Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007; 369: 836-843.
15. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-596.
16. Bellomo R, Ronco C, Kellum JA, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-R212.
17. Viaene E, Chanteux H, Servais H, et al. Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002; 46: 2327-2332.
18. Arlicot N, Rochefort GY, Schlecht D, et al. Stability of antibiotics in portable pumps used for bronchial superinfection: guidelines for prescribers. Pediatrics 2007; 120: 1255-1259.
19. Zhang Y, Trissel LA. Stability of piperacillin and ticarcillin in Auto-Dose infusion system bags. Ann Pharmacother 2001; 35: 1360-1363.
20. Carroll JA. Stability of flucloxacillin in elastomeric infusion devices. J Pharm Pract Res 2005; 35: 90-92.
21. Smith DL, Bauer SM, Nicolau DP. Stability of meropenem in polyvinyl chloride bags and an elastomeric infusion device. Am J Health Syst Pharm 2004; 61: 1682-1685.
22. Patel PR, Cook SE. Stability of meropenem in intravenous solutions. Am J Health Syst Pharm 1997; 54: 412-421.
23. Udy AA, Varghese JM, Altukroni M, et al. Subtherapeutic initial p-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest 2012; 142: 30-39.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13: 818-829.
25. Davis JS, Cheng AC, McMillan M, et al. Sepsis in the tropical Top End of Australia's Northern Territory: disease burden and impact on Indigenous Australians. Med J Aust 2011; 194: 519-524.
26. Fuster-Lluch O, Gerónimo-Pardo M, Peyro-Garcia R, Lizán-Garcia M. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth Intensive Care 2008; 36: 674-680.
27. Brunkhorst FM, Oppert M, Marx G, et al. Effect of empirical treatment with moxifloxacin and meropenem vs meropenem on sepsis-related organ dysfunction in patients with severe sepsis: a randomized trial. JAMA 2012; 307: 2390-2399.